Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 9—September 2024
Research

Medical Costs of Nontuberculous Mycobacterial Pulmonary Disease, South Korea, 2015–2019

Shihwan Chang1, Sol Kim1, Young Ae Kang, Moo Suk Park, Hojoon Sohn2, and Youngmok Park2Comments to Author 
Author affiliations: Yonsei University College of Medicine, Seoul, South Korea (S. Chang, S. Kim, Y.A. Kang, M.S. Park, Y. Park); Severance Hospital, Seoul (S. Chang, S. Kim, Y.A. Kang, M.S. Park, Y. Park); Seoul National University College of Medicine, Seoul (H. Sohn); Seoul National University Institute of Health Policy and Management, Seoul (H. Sohn)

Main Article

Table 2

Baseline characteristics of participants in study of medical costs of nontuberculous mycobacterial pulmonary disease, South Korea, 2015–2019*

Variable Total, n = 147
Age at diagnosis, y, median (IQR) 61.0 (54.0–66.0)
Female
 100 (68.0)
Comorbidity
History of tuberculosis 29 (19.7)
History of NTM treatment 5 (3.4)
Bronchiectasis 36 (24.5)
Chronic obstructive pulmonary disease 21 (14.3)
Asthma 11 (7.5)
Lung cancer 3 (2.0)
History of thoracic operation 12 (8.2)
Hypertension 10 (6.8)
Diabetes mellitus 6 (4.1)
Other malignancy
 17 (11.6)
Causative species
M. avium complex 112 (76.2)
M. abscessus 15 (10.2)
M. kansasii 10 (6.8)
M. fortuitum 2 (1.4)
Other†
 8 (5.4)
Duration, mo, median (IQR)
Total duration of follow-up 49.7 (33.0–68.2)
Prediagnostic 0.2 (0.0–2.2)
Pretreatment 3.5 (1.9–8.2)
Treatment 14.8 (13.3–18.4)
Post-treatment
 19.5 (9.6–35.6)
No. outpatient visits, median (IQR) 23.0 (18.0–33.0)
No. admissions, n = 71, median (IQR) 1.0 (1.0–2.0)
Length of stay per admission, d, median (IQR) 6.0 (2.0–15.5)
Total length of stay, d, median (IQR)
 9.0 (3.0–30.0)
Treatment outcome
Culture conversion 115 (78.2)
Microbiologic cure 101 (68.7)
Retreatment for recurrence
 13 (8.8)
All-cause mortality 6 (4.1)

*Data are presented as no. (%) patients except as indicated. NTM, nontuberculous mycobacteria. †Includes mixed infections.

Main Article

1These first authors contributed equally to this article.

2These authors were co–principal investigators.

Page created: July 30, 2024
Page updated: August 22, 2024
Page reviewed: August 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external